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Various predictors for an increased risk of
abdominal aortic aneurysm (AAA) rupture are
known, such as aneurysm size and growth rate,
smoking, chronic obstructive pulmonary disease
(COPD) and hypertension.1-4 A promoting effect of
prolonged corticosteroid treatment on aneurysm
growth has been suggested1,5-10; however, an asso-
ciation between chemotherapy and AAA expansion
has not yet been established. We report a case of
AAA rapid growth and rupture in a 73-year-old man
who received chemotherapy with gemcitabine, cis-
platinum, prednisone, and dexamethasone for
metastatic pancreatic carcinoma.
CASE REPORT
In December 1997, a 73-year-old normotensive male
physician had a palpable pulsatile mass in the lower
abdomen and a 6-week history of lower back pain. His
medical history was significant for polymyalgia rheumat-
ica. The patient had normal blood cholesterol levels, was
a nonsmoker, and did not drink alcohol. Of note was
that his mother died of pancreatic cancer at the age of 70
years. On physical examination, blood pressure was
120/70 with a heart rate of 80 beats per minute. There
was a palpable pulsatile mass in the lower abdomen. The
remainder of the physical examination was normal,
including the pulses at all levels. Results from all labora-
tory tests were normal. A contrast enhanced computed
tomography (CT) scan revealed an AAA of 5.8 cm in
largest diameter (Figs 1 and 2, A) and bilateral iliac
artery aneurysms. Additionally, a 1.5-cm mass was pre-
sent in the tail of the pancreas. In January 1998, an open
AAA repair with removal of the pancreatic tail mass was
planned. Endovascular aneurysm repair was not attempt-
ed because of the anatomy of the bilateral iliac aneurysms
and the need for exploration of the pancreatic mass.
During surgery there was gross evidence of metastatic
disease. Biopsies of the hepatic lesions confirmed a
metastatic adenocarcinoma of primary pancreatic origin.
Because there was no evidence of an impending AAA
rupture, neither AAA repair nor removal of the pancre-
atic tail mass was performed. A pancreatic tumor and
multiple liver lesions up to 1.2 cm in size were demon-
strated in a subsequent CT scan in March 1998. At that
time, the AAA was 5.9 cm in largest diameter (Fig 1).
Chemotherapy with gemcitabine (1 g/m2 weekly for 3
weeks every 5 weeks) was initiated. The size of the AAA,
the pancreatic mass, and the hepatic lesions was followed
closely with CT scans. Initially the chemotherapy was
accompanied by a prednisone dose of 10 mg/d.
However, prednisone was discontinued after 4 weeks
because the patient refused further steroid medication.
On September 28, 1998, chemotherapy was suspended
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according to the patient’s wishes. Up to this time, the
AAA had grown to 6.6 cm in largest diameter (Fig 1).
Chemotherapy was restarted in January 1999 (gem-
citabine as previously dosed with cisplatinum added at 30
mg/m2). Additional medication included dexametha-
sone at a dose of 10 mg/d (later 12 mg/d), started
January 1999. In February 1999, AAA rupture was clin-
ically suspected and confirmed by a subsequent CT scan.
At this time the size of the AAA had increased to 7.1 cm
in largest diameter (Fig 2, B, C). Although an emergency
AAA repair was successfully performed on February 8,
1999, the patient died of his pancreatic cancer on March
21, 1999.
DISCUSSION
The current concept of AAA pathogenesis has
recently been reviewed in detail.11-15 Key roles in
AAA pathogenesis have been attributed to the
decreased elastin concentration and smooth muscle
cell (SMC) number; increased collagen concentra-
tion and elastolytic activity, mainly matrix metallo-
proteinases; and an underlying inflammatory
response. In this case we have noted unusually rapid
aneurysm expansion of 1.3 cm within little more
than a year (0.7 cm within the first phase of
chemotherapy, equivalent to a growth rate of 1.2
cm/y, Fig 1). Published expansion rates for AAAs of
this size range from 0.29 ± 0.9 cm/y to 0.94
cm/y.16,17 Limet et al2 reported a growth rate of
0.75 ± 0.13 cm/y in AAAs larger than 5 cm in max-
imum diameter and showed that aneurysm size itself
influences the growth rate in an exponential man-
ner.2,18 In our patient we observed a 3-month stag-
nation in aneurysm growth after expansion in size
over 10 months. This stagnation coincided with the
pause in chemotherapy (Fig 1).
Initially our patient received daily doses of pred-
nisone. Lindholt et al1 attribute the high prevalence
of AAA in patients with COPD to medications
commonly used in COPD (such as steroids) rather
than to a common pathogenic pathway. They found
the mean AAA annual expansion in patients who
used oral steroids to be 1.8-fold higher than in the
control group. An increased aneurysm growth rate
possibly related to steroid treatment has also been
noticed in the immunosuppressed transplant popu-
lation.19 However, adverse effects of other
immunosuppressive drugs may contribute to
aneurysm development, such as cyclosporine-
induced hypertension.19 Smith and Hirst5 reported
two cases of spontaneous thoracic aortic aneurysm
rupture associated with chronic steroid therapy for
rheumatoid arthritis. A case of aortic dissection in a
patient with lupus who had been treated with
steroids has been described by Hussain et al.6 In
addition, steroids have been shown to induce aortic
rupture in heterozygous female Blotchy mice (in
90% of animals within 2 weeks), as well as in healthy
mice (in 20% of animals within 2 weeks).7 Similar
effects have been observed in various other
rodents.8-10 On the other hand, in a rat inflamma-
tory aneurysm model, steroids partially inhibited
secondary aneurysm enlargement.20 However,
steroids are thought to inhibit SMC proliferation.
This was shown in airway SMCs21 and fibroblasts.22
Kahari23 also reports a suppression of elastin gene
expression in fibroblasts. This effect may also hold
true for AAA and therefore contribute to the disad-
vantageous effect on AAA of long-term steroid
treatment.1,5-10
In our patient, steroid treatment was suspended
after 4 weeks. In the following 4 months with
chemotherapy but no steroid treatment, the
aneurysm expanded 0.5 cm (Fig 1). Steroid treat-
ment with dexamethasone was resumed 2 weeks
before rupture. We therefore assume that pred-
nisone therapy in this case was not the major cause
of accelerated aneurysm growth. However, during
the last 2 weeks, treatment with dexamethasone
might have contributed to aneurysm enlargement.
Very little work has been published on the effect
of chemotherapy on the extracellular matrix. Golden
et al24 report a case of aortic dissection in a patient
receiving chemotherapy for Hodgkin’s disease.
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Fig 1. Time course of aneurysm expansion, chemothera-
py, and steroid therapy.
Unfortunately, they do not discuss the differential
effects of each component of their patient’s
chemotherapeutic regimen, which also included a
glucocorticoid. To our knowledge this is the only
case report describing large artery rupture possibly
resulting from chemotherapy. Most published work
investigates vascular complications other than large
artery aneurysm formation or rupture. The broad
spectrum of vascular toxicity associated with anti-
neoplastic agents has been reviewed by Doll and
Yarbro.25
Gemcitabine (Gemzar) (chemical name, 2’-2’-
difluorodeoxycytidine), a new nucleoside, is increas-
ingly used in the chemotherapy of pancreatic cancer.26
After intracellular phosphorylation, gemcitabine
inhibits DNA synthesis and also reduces cellular
deoxynucleotide concentrations.27 In pancreatic can-
cer, gemcitabine was found to alleviate cancer-related
symptoms, including pain, decreased performance
status, and weight loss, and to lengthen survival time
(median survival, 5.65 months as compared with 4.41
months with fluorouracil treatment).28
The first clinical studies with the anticancer agent
cisplatinum were reported in 1974.29 After intracel-
lular activation, cytotoxic effects of cisplatinum
appear to target DNA directly by the formation of a
variety of stable bifunctional adducts.30 In combina-
tion with gemcitabine, synergistic effects have been
suggested.31
In our case, it is remarkable that the fastest
aneurysm growth coincided with chemotherapy
administration. Whereas the AAA grew 0.7 cm dur-
ing the first 7 months of chemotherapy with gem-
citabine alone and 0.5 cm during the last month of
chemotherapy with gemcitabine and cisplatinum,
there was no aneurysm growth when chemotherapy
was not given for 3 months (Fig 1). Therefore, it
seems reasonable to consider a possible correlation
between chemotherapy and aneurysm growth.
Chemotherapy might have disadvantageous effects
on AAAs. Potential mechanisms may involve inhibi-
tion of SMC proliferation and collagen and elastin
synthesis.
Unfortunately, chemotherapy in pancreatic can-
cer still remains a largely palliative approach.
However, if in other cancers curative chemotherapy
is intended, it may be reasonable to lower the
threshold for surgical AAA repair. In view of this
novel potential adverse effect, chemotherapy should
be used with caution in patients with AAA.
Recommendations on follow-up examination of
patients with AAA vary depending on aneurysm size
and increment of AAA expansion at the last exami-
nation.16,18 At this point, the possible contribution
of chemotherapy to accelerated aneurysm growth
cannot be ruled out. Therefore, more frequent
monitoring of AAAs in patients with large
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Fig 2. A, CT scan from December 24, 1997 (level L4, AAA
5.8 cm in largest diameter). B, CT scan from February 8,
1999 (level L4, AAA 7.1 cm in largest diameter). C, CT
scan from February 8, 1999 (level L5, AAA rupture).
A
B
C
aneurysms is recommended while they are receiving
chemotherapy.
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